Iovance Biotherapeutics. has filed a patent for treating double-refractory metastatic melanoma using tumor infiltrating lymphocytes (TILs). The method involves administering TILs to patients with melanomas resistant to other therapies. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Iovance Biotherapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of January 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of double-refractory metastatic melanoma using tils

Source: United States Patent and Trademark Office (USPTO). Credit: Iovance Biotherapeutics Inc

A recent patent publication (Publication Number: US20230414662A1) discloses a method for treating double-refractory metastatic melanoma in patients by administering a therapeutically effective population of tumor infiltrating lymphocytes (TILs). The method involves obtaining TILs from a resected tumor, expanding them in a closed system, and administering them to the patient. The patent specifies various scenarios where the metastatic melanoma is refractory to specific treatments like aldesleukin, pembrolizumab, nivolumab, ipilimumab, BRAF inhibitors, and PD-1 or PD-L1 inhibitors, among others. Additionally, the method includes steps for culturing TILs, supplementing with IL-2 and antigen presenting cells, and administering a non-myeloablative lymphodepletion regimen before TIL infusion.

Furthermore, the patent outlines detailed steps for processing TILs, expanding them in a closed system, and administering them to patients with double-refractory metastatic melanoma. The method involves multiple expansions of TILs to generate a therapeutic population, ensuring a significant increase in TIL numbers. It also includes co-administration with other treatments like CTLA-4 inhibitors, BRAF inhibitors, MEK inhibitors, and chemotherapeutic regimens in specific cases. The patent emphasizes the importance of closed systems, specific cytokine combinations in cell culture medium, and lymphodepletion regimens for optimal treatment outcomes. Additionally, the method specifies the use of IL-2 regimens post-TIL infusion and provides a range for the therapeutically effective population of TILs to be administered to patients.

To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies